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Kawasaki disease is an acute vasculitis with a particular involvement of the coronary
arteries. Coronary artery aneurysms develop in 20% of untreated children. It has been
shown that early treatment with intravenous immunoglobulins and aspirin decreases
this risk to 5%, but the medium to long term prognosis of children with Kawasaki
disease is still unclear. To determine the outcome of the disease and risk factors for
poor evolution, we reviewed retrospectively the medical records of all patients with a
diagnosis of Kawasaki disease at our Institution between 1981 and 2014. Among the
207 patients included in the study, 96 patients had coronary diameter anomalies (46.4%)
at diagnosis and children with atypical ages for Kawasaki disease (<1 year or >10 year
of age) were more often affected with aneurysms or dilatations. Eighty-four of them had
complete regression of coronary aneurysms during the follow-up (87.5%) Absence of
immunoglobulins in the acute phase was associated with less regression rate (57.1 vs.
92.2%), and boys had greater z-scores at last echocardiography, statistically significant
for the left anterior descending artery. We found rare complications after the acute phase
documented in our patient charts (only 3.8%). Recurrence of the disease occurred in
5 children (2.4%) and myocardial ischemia in 3 patients (1.4%), all with initial coronary
aneurysm.
Conclusion: Medium to long term prognosis after Kawasaki disease is excellent. Boys,
patients not treated with immunoglobulins or outside the usual age range are more at
risk for an unfavorable outcome.
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INTRODUCTION
Kawasaki disease (KD) is an acute systemic vasculitis of early childhood considered the leading
cause of acquired heart disease in children in developed countries. Cardiac lesions are a hallmark
of KD and coronary artery aneurysms (CAA) develop in 20% of untreated children and can lead to
coronary stenosis, myocardial infarction (MI), or sudden death. Pericarditis complicated by cardiac
tamponade or myocarditis associated with myocardial dysfunction can also occur during the acute
phase (1, 2).
Despite almost 50 years of research, the etiology of KD remains unknown. An infectious
trigger which causes an excessive inflammatory response in genetically predisposed children is a
widespread hypothesis, but no specific pathogen has been identified yet (3).
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KD has been reported in almost every country, with variable
incidence rates (4). Over the past decades, the worldwide
incidence has been increasing in most countries. KD occurs
predominantly in children<5 years of age, with a peak incidence
between 12 and 24 months (5–10).
Without a specific diagnostic test, the diagnosis of KD is
based on clinical criteria, established by the Japanese Ministry
of Health Research Committee and adopted by the American
Heart Association, which include fever >39◦C for at least 5
days (or less if shortened by treatment for KD) plus four of
the five main clinical features: rash, conjunctivitis, oral mucosal
changes, changes in the extremities, lymphadenopathy. In some
cases, KD presentation is incomplete and echocardiographic and
laboratory findings have an important role in the diagnosis
(11–14).
Conventional therapy associates intravenous
immunoglobulin (IVIG) and high-dose aspirin (ASA). Early
administration of IVIG reduces the risk of CAA to 5% (15–18).
About 15–20% of patients are unresponsive to this initial
treatment and will need repeat or additional treatment such as
corticosteroids or infliximab (19, 20).
Mortality rates are low and the majority of patients are
considered to have an excellent prognosis but long-term
cardiovascular outcome is not totally defined (21–25). Only
males with cardiac sequelae are known to have a higher
mortality rate than the general population (26). However, even
for patients with regressed CAA, there may be a possible
cardiovascular dysfunction years after the acute phase, secondary
to increased arterial stiffness, abnormal endothelial function,
intimal thickening or calcification of coronary arteries (1, 11, 27–
31). The clinical relevance of those changes is unclear and long-
term follow up of patients depends on the degree of coronary
involvement.
Because the prognosis of patients with a diagnosis of KD
is not well defined, we decided to conduct this study to
determine the characteristics and outcome of all patients at our
Institution between 1981 and 2014 and to highlight risk factors
for unfavorable evolution.
MATERIALS AND METHODS
Patients and Study Design
This is a retrospective study including all patients with a diagnosis
of pediatric KD, followed in the Pediatric Cardiology Unit at the
University Hospital of Lausanne.
We analyzed retrospectively the medical records of all
patients up to 18 years of age at diagnosis, with complete
or incomplete KD and followed in the Pediatric and Adult
Cardiology Unit of the University Hospital of Lausanne
from January 1981 to March 2014. The following variables
were documented: epidemiologic and clinical features,
laboratory and echocardiographic data, treatment regimen,
Abbreviations: ASA, Aspirin; BSA, Body Surface Area; CAA, Coronary Artery
Aneurysm; IVIG, Intravenous Immunoglobulin; KD, Kawasaki Disease; LAD, Left
Anterior Descending Coronary Artery; LMCA, Left Main Coronary Artery; MI,
Myocardial Infarction.
complications during the acute phase (shock, heart failure,
cerebral injury, aseptic meningitis, uveitis, renal dysfunction,
haemolysis, and pancreatitis) and during the follow-up
(death, recurrence, ischemia, surgical or catheter coronary
interventions).
Patients were excluded from the study if the diagnosis of KD
was rejected or if there were missing information in their medical
records.
The study protocol was approved by the Cantonal Ethics
Committee Vaud.
Definitions
A KD case was defined as: fever for 5 days or more (unless IVIG
treatment was begun before the 5th day of fever), exclusion
of any other diagnosis, and any four of the five principal
clinical features. Incomplete KD was defined according to the
guidelines of the American Heart Association as fever for 5
days or more, <4 diagnosis criteria and echocardiographic
abnormalities or a set of suspect laboratory criteria
(1).
First day of fever was defined as day 1 of illness.
Cardiovascular Assessment
Cardiovascular complications, including coronary artery lesions,
pericarditis, myocarditis, valvular regurgitations and heart
failure, were assessed during the acute phase and during the
follow-up at 3 different periods of time (6 month to 18 months,
3 to 6 years, 8 years and more). The coronary involvement
(dilatation, small, medium, giant CAA) was determined by the
z-scores adjusted to patients’ body surface area (BSA) (Boston
formula), if available. We used the z-score stratification proposed
by AHA guidelines (2017) to determine the degree of coronary
involvement (32):
1. No involvement: Z score always <2
2. Dilation only: Z score 2 to <2.5; or if initially <2, a decrease
in Z score during follow-up ≥1
3. Small aneurysm: Z score ≥2.5 to <5
4. Medium aneurysm: Z score ≥5 to <10, and absolute
dimension <8 mm
5. Large or giant aneurysm: Z score≥10, or absolute dimension
≥8 m
If z-scores could not be calculated because of missing details
about coronary diameters, the degree of involvement was based
on cardiologist report.
Statistical Analysis
Statistical analysis was performed using the statistical software
STATA 14. Continuous variables are reported as median
and range (minimum, maximum). Categorical data are
reported by percentage. Pearson’s chi-squared test was
used to compare distribution between groups, separated
by sex, age, treatment regimen, KD presentation (complete
vs. incomplete). A p < 0.05 was considered statistically
significant.
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RESULTS
Patients’ Characteristics
During the study period, 229 patients with KD were diagnosed at
the University Hospital of Lausanne. Twenty-two were excluded
because of missing information in their medical file.
Of the 207 children included, 58.9% were male (n= 122), with
a sex ratio of 1.43.
The median age at onset of KDwas 32 months (range 1 month
to 15 years). The majority of patients were less than 5 years of age
(76.8%, n= 159). Age distribution is shown in Figure 1.
KD was complete in 146 cases (70.5%) and incomplete in 61
cases (29.5%). The annual number of incomplete KD increased
after 1996: only 7 (17%) children were diagnosed with incomplete
KD from 1981 to 1996 compared to 54 (32.5%) cases after 1996.
Patients with incomplete KD were younger at diagnosis than
patients with complete KD, but with no statistically significant
difference (26 vs. 35 months, p = 0.08). The diagnosis, and
therefore treatment, of patient with incomplete KD was delayed
compared to complete KD (median duration before diagnosis 6.5
vs. 8 days, p= 0.007).
The diagnostic criteria and other clinical features are
summarized in Table 1. There was no statistically significant
difference in disease presentation according to sex or age.
FIGURE 1 | Age at onset of KD.
TABLE 1 | Clinical features at presentation.
Diagnostic
criteria
Other clinical features
Polymorphus rash n = 176
(85%)
GI tract (diarrhea, vomiting,
abdominal pain, hematemesis)
n = 121
(58.4%)
Changes in lips
and oral cavity
n = 161
(77.8%)
Respiratory/ORL (cough,
dyspnea, pneumonia, sinusitis,
epistaxis, pharyngitis)
n = 60
(30.4%)
Conjonctival
injections
n = 159
(76.8%)
Musculoskeletal (arthralgia,
myalgia, joint effusion)
n =30
(14.6%)
Changes of the
extremities
n = 144
(69.9%)
Neurological (seizure,
meningism, headache, dizziness,
lethargy, photophobia)
n = 24
(11.6%)
Cervical
adenopathy
n = 136
(65.7%)
Genito-urinary (hematuria,
proteinuria, oliguria, urinary
infection)
n = 18
(8.7%)
Cardiac (murmur) n =2
(1%)
KD Occurrence
The University Hospital of Lausanne is a leading tertiary center
that covers an overall population of around 1,400,000 person.
Every child within this area with a suspected diagnosis of KD
is referred for echocardiographic evaluation to its pediatric
cardiology unit.
As shown in Figure 2, KD was diagnosed at least in one child
every year except in 1984, and there is an increase in the number
of patients identified over the years with a peak of 22 patients in
2012.
A non-significant seasonal variability was noted, with a
highest incidence in winter (29.5% of KD occurred in winter,
which represents 61 patients).
Treatment
Treatment during the acute phase of KD is summarized in
Figure 3. All patients received a first infusion of IVIG, except 16
children (7.7%). Half of them were diagnosed before IVIG was
available at our Institution. The other half was diagnosed after
more than 7 days of evolution.
One hundred and Sixty Five patients (86.4%) received a single
IVIG infusion of 2 g/kg, the other patients received 0.4 g/kg for
4–5 days (13.1%, n= 25) or 1 g/kg for 2 days (0.5%, n= 1). IVIG
therapy was well tolerated and only 8 patients (3.9%) developed
side effects (allergic reaction, hypotension).
A majority of children also received ASA (97.1%, n = 201).
High dose of ASA (80–100 mg/kg/day) was given in the majority
of cases (86.1%, n = 173). This dose was usually reduced to 5
mg/kg/day after the acute phase.
FIGURE 2 | Occurrence rates.
FIGURE 3 | Treatment during the acute phase.
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Fifteen treated patients (7.2%) also received steroids
during their hospitalization. Reasons for using steroids
were either severe coronary anomalies or associated severe
complications such as shock, respiratory distress, pancreatitis,
renal insufficiency, ascites, pleural effusion, and pancytopenia.
Antibiotics were given in 31 cases (15% of treated patients),
concomitantly or before diagnosis.
Three patients (1.4%) were diagnosedwith KD aftermore than
2 weeks of evolution and were not treated either with IVIG or
ASA since they had no residual inflammatory changes.
The majority of patients (58.5%, n = 121) were treated before
day 7 of illness (median: day 7; range: day 1–39). However, 22.7%
of patients (n = 47) did not received a treatment before the 10th
day of illness.
Thirty-four children (16.4%) needed a 2nd therapy because
of persistent or recrudescent fever after the initial treatment:
24 patient a 2nd IVIG infusion, 8 patients received steroids
associated to IVIG. Infliximab was added to this latter treatment
once. Steroids alone were used in 1 case (3%).
Three children needed a 3rd treatment for persistent fever
(1.4%): a 3rd IVIG infusion (n = 1), corticosteroid associated to
Anakinra (n= 1) and Infliximab (n= 1).
There was no difference in gender, age distribution or KD
presentation between IVIG responders and non-responders.
Information about treatment after the acute phase was
available for 200 children (96.6%). Patients were treated with ASA
more than 1 year after the onset of KD in 29 cases (14%). The
median duration of treatment after the acute phase was 2 months
(range 0 month to 34 years). At the end of the study period, 11
patients (5.3%) were still under treatment. Every patient received
low-dose (5–10 mg/kg/day) ASA and additional acenocoumarol
was given in 1 child with persistent giant CAA.
Echocardiography
Results of echocardiography during the acute phase of KD were
available for all patients except for 3 Swiss children who were
diagnosed with KD and treated abroad during their holidays.
The echocardiography findings at diagnosis are summarized in
Table 2.
Z-scores could be calculated in 171 echocardiograms (82.6%),
the other 36 did not report the exact diameters of the coronary
arteries. After the z-score calculation, the degree of coronary
involvement was modified from the echocardiographic report
in 90 cases (52.6% of the patients with z-score). Cardiologists
underestimated the coronary artery lesions in 70 patients (40.9%)
and overestimated them in 20 patients (11.7%).
The initial echocardiography showed anomalies in 136 cases
(65.7%). Perivascular brightness of coronary arteries was the
most common finding (52.6%, n = 109), followed by changes in
coronary arteries diameter (46.4%, n= 96).
Isolated left coronary artery lesions (25.6%, n = 53) were
more frequent than isolated right coronary artery lesions (4.8%,
n= 10). Bilateral abnormalities occurred in 33 patients (15.9%).
In order of decreasing frequency, the sites of left coronary
involvement were the left anterior descending coronary artery
(LAD) (51.1% of left coronary artery lesions, n = 44), both LAD
and left main coronary artery (LMCA) (25.6%, n = 22), isolated
LMCA (23.2%, n = 20). LMCA did not present any giant CAA.
Multiple CAA on the same coronary artery occurred in only one
patient (0.5%).
No patient suffered fromMI during the acute period.
Patients with atypical ages for KD (<1 or >10 year of age)
had a higher incidence of changes in coronary arteries diameter
(atypical age: 62.8% of coronary artery lesion vs. age 1–10 year:
43%, p = 0.01, see Table 3). Giant CAA occurred in 11.4% of
patients with an atypical age and 1.7% in the 1–10 year old group.
Valvular involvement occurred in 19.8% of patients (n = 41)
and most often affected the mitral valve (87.8% of valvular
dysfunction, n = 36). Fifty patients (27%) suffered from
pericarditis.
Death
Of the 207 patients, 1 died during the acute phase. This
corresponds to a mortality rate of 0.5%. The deceased patient
was a 33 months old boy. He developed cardiac tamponade,
pulmonary hypertension and vena cava thrombus treated with
thrombolysis and heparin. He died of subsequent cerebral
hemorrhage 13 days after onset of KD.
Follow-Up
Echocardiography report after the acute phase of KD was
available in the majority of cases (97.1%, n = 201). The patients
were followed up for a median duration of 21 months (range
0 month to 30 years). The patients without echocardiography
follow-up were 6 children diagnosed between 1982 and 2010 who
did not have any CAA and no subsequent follow-up appointment
was planned for them.
Three different time frames from the time of diagnosis were
selected for the echocardiographic follow-up: 6 to 18 months, 3
TABLE 2 | Echocardiography results at diagnosis.
Perivascular brightness of coronary arteries n = 109
(52.6%)
Coronary dilatation n = 16
(7.7%)
Coronary aneurysm:
- Small n = 41
(19.8%)
- Medium n = 32
(15.4%)
- Giant n = 7 (3.4%)
Pericarditis:
- Pericardial effusion n = 54
(26.1%)
- Cardiac tamponade n = 2 (1%)
Valvular disease n = 41
(19.8%)
Myocarditis:
- Decreased ejection fraction of the left ventricle n = 12 (5.8%)
- Congestive heart failure n = 3 (1.4%)
Arrhythmia n = 4 (1.9%)
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TABLE 3 | Coronary involvement according to age, sex and IVIG treatment.
Study
population
(n= 207)
Age 1-10
year
(n = 172)
Atypical
age
(n = 35)
P-value Males
(n= 122)
Females
(n = 85)
P-value IVIG
(n= 191)
No IVIG
(n = 16)
CAA at
diagnosis
Normal 111 (53.6%) 98 (56.9%) 13 (37.1%) 0.01 61 (50%) 50 (58.8%) NS 100 (52.3%) 11 (68.7%) NS
Dilatation 16 (7.7%) 14 (8.1%) 2 (5.7%) 0.01 8 (6.5%) 8 (9.4%) NS 15 (7.8%) 1 (6.2%) NS
Small CAA 41 (19.8%) 34 (19.7%) 7 (20%) 0.01 26 (21.3%) 15 (17.6%) NS 39 (20.4%) 2 (12.5%) NS
Medium CAA 32 (15.4%) 23 (13.4%) 9 (25,7%) 0.01 22 (18%) 10 (11.7%) NS 32 (16.7%) 0 (0%) NS
Giant CAA 7 (3.4%) 3 (1.7%) 4 (11.4%) 0.01 5 (4.1%) 2 (2.3%) NS 5 (2.6%) 2 (12.5%) NS
CAA at last
follow-up
Normal 194 (93.7%) 162 (94.2%) 32 (91%) NS 111 (90.9%) 83 (97.6%) NS 181 (94.7%) 13 (81.2%) NS
Dilatation 1 (0.5%) 1 (0.58%) 0 (0%) NS 0 (0%) 1 (1.2%) NS 1 (0.5%) 0 (0%) <0.001
Small CAA 5 (2.4%) 4 (2.3%) 1 (2.9%) NS 5 (4.1%) 0 (0%) NS 5 (2.6%) 0 (0%) <0.001
Medium CAA 3 (1.4%) 3 (1.74%) 0 (0%) NS 3 (2.4%) 0 (0%) NS 3 (1.6%) 0 (0%) <0.001
Giant CAA 3 (1.4%) 2 (1.16%) 1 (2.9%) NS 2 (1.6%) 1 (1.2%) NS 1 (0.5%) 2 (12.5%) <0.001
Tortuous 1 (0.5%) 0 (0%) 1 (2.9%) NS 1 (0.8%) 0 (0%) NS 0 (0%) 1 (6.2%) <0.001
Bold values are values that are statistically significant.
to 6 years, 8 years and more. A follow-up echocardiogram at 6 to
18 months was performed in 137 patients (66.2%, median time
12 months). Forty-five patients had an echocardiography follow-
up at the second time frame (21.7%, median time 4 years) and 34
patients after 8 years or more (16.4%, median time 10 years).
Comparison between initial coronary artery diameter
and at different time frames is shown in Figure 4. 89.8%
of patients (n = 123) had normal coronary artery at first
follow-up (6–18 months) echocardiography, compared
to 82.3% (n = 28) at the last one. This is not related
to recurrence of cardiac abnormalities but to a longer
duration of the follow-up of patients with cardiac
sequelae.
The first follow-up echocardiography (6–18 months) showed
normal coronary artery in almost 90% of patients, compared to
34.3% in the initial one. This large difference is related to CAA
and coronary dilatation or perivascular brightness regression:
of the 96 patients with initial changes in coronary arteries
diameter, 84 (87.5%) had only a transient abnormality and CAA
or dilatation regressed over time. Regression occurred mostly
within 3 months (range 2 weeks to 19 years) and only 7 of the
84 patients (8.3%) with transient abnormality had regression 2
years or more after the acute phase. Dilatations were transient
in 93.7% of cases (15 patients of the 16 with initial dilatation),
small CAA in 92.6% (38 of the initial 41), medium CAA in 84.3%
(27 of the initial 32). Of the seven patients with giant CAA, two
showed complete resolution, three partial regression, and the last
two stayed giant.
Absence of IVIG in the acute phase was associated with less
regression rate (57.1 vs. 92.2%, p = 0.07), and this association
was especially important for giant CAA persisting at last
echocardiography (0.5% of giant CAA in IVIG group vs. 12.5%
if no IVIG was given during the acute phase, see Table 3). In
addition, boys had greater z-score at last follow-up, statistically
significant for the LAD (boys: median z-score 1.28, range 0.06–
18.4/girls: median z-score 0.9, range 0.01–2/p= 0.03).
FIGURE 4 | Comparison between initial coronary artery diameter and at
different time.
Complications of KD during follow-up occurred in 8 patients
(3.8%). The most frequent complication was recurrence of KD
(n = 5, 2.4%). Of those with recurrence, the 2nd onset of KD
happened within 1 year of the acute phase in 3 cases (60%)
and within 1 to 5 years for the 2 (40%). MI occurred in 3
patients (1.4%): one patient had antero-septal MI within 1 year
of the onset of KD, the other two had signs of ischemia on
stress-MRI or myocardial perfusion scintigraphy 5–10 years after
KD. Surgery was performed in one of them (coronary artery
reimplantation). MI affected only children with initial CAA.
Twenty-nine patients were treated with ASA for 1 year or more
(14%) and 7 for more than 10 years (3.4%). We found no
statistically significant predictive factor for the occurrence of
long term complication. However, the absence of IVIG treatment
during the acute phase was associated with more complications
during the follow-up, but with no statistically significant
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difference (No IVIG: 12.5% of complications vs. IVIG: 3.6%,
p= 0.09).
DISCUSSION
This is the 1st study of medium to long-term follow-
up of children diagnosed with KD at our Institution. The
epidemiological characteristics, with a majority of patients <5
years of age with predominance of male gender and the seasonal
trends, were similar to those reported in other studies from
other countries (9, 14, 33–35). Incomplete KD rates were higher
than expected, with 29.5% of incomplete cases compared to
20% in other studies. This difference may be associated with
a high index of suspicion of this presentation of the disease
at our Institution. However, patients with incomplete KD were
identified and treated later than the other, highlighting the
difficulty in identifying these patients. In any case, it is crucial
for physicians to maintain a high index of suspicion for every
child presenting with symptoms suggestive of KD. Increase in
incomplete KD over time was also reported in other articles
(5, 10).
The occurrence of KD has increased over time, as found in
other studies (4, 5). Part of this increase may be related to a better
diagnosis of KD associated with a highest awareness of the disease
and an improvement in the imaging modalities.
Many non-specific clinical features were present in addition
to the diagnostic criteria. This polymorphous presentation of
KD makes the diagnosis even more challenging, with a large
differential diagnosis.
The majority of children received treatment before the 7th
day of illness, but there were still 22.7% of patients with a late
therapy due to late diagnosis. This rate in delayed treatment is
similar to other studies, but it is crucial to improve diagnosis and
early therapy as we found that IVIG treatment during the acute
phase is associated with greater regression rate and, thus, with less
cardiac sequelae.
Other therapies were used in the acute phase, such as
corticosteroids, IL-1 receptor antagonist or TNF inhibitor. The
role of those treatments is not adequately assessed yet and it
would be useful to clarify their indications.
The proportion of IVIG non-responders was comparable to
other studies (32). We found no differences in terms of gender
or age between IVIG responders and non-responders, as seen in
other studies (29, 36).
Treatment of patients who fail to respond to initial therapy
is not fully standardized but American Heart Association
recommend retreatment with à 2nd infusion of IVIG (evidence
level B). In our study, the majority of patients received a 2nd dose
of IVIG but further studies would be needed to define clearly the
best therapy for the non-responders.
The proportion of patients with abnormal echocardiography
at diagnosis was high (65.7%). This number is high because it
includes perivascular brightness. If we look only at coronary
artery diameters, 46.4% patients developed abnormalities, with
7.7% of dilatation and 38.6% of CAA. This number of dilatation
and CAA is higher than expected (8, 18, 33) and is a consequence
of an increased recognition of these lesions, as we used z-
score in this study. Indeed, it has been established that z-score
allow for better evaluation of the severity of coronary artery
changes by correcting for BSA, unlike the Japanese criteria that
underestimate coronary involvement (1, 32, 37, 38). Z-score
calculations changed the degree of coronary artery involvement
from the initial echocardiographic report in more than 50% of
patients, which had underestimated the coronary artery lesion in
the majority of cases. This fact shows how essential the z-score
calculations is in KD. However, z-score use has to be done with
caution, as it is proved that small error in measurement of the
coronary artery diameter can produce large difference in z-score
calculation (32). Furthermore, accurate measurement of BSA can
be difficult in irritable young children. As seen in other studies,
patients with atypical ages for KD (<1 or >10 year of age) had
a higher incidence of coronary artery dilatations and aneurysms
(10, 34). Sites of coronary artery lesions were comparable to other
study: the left coronary artery (LAD> LMCA) was more affected
than the RAD (39).
Pericarditis rate was in agreement with other studies (18). As
expected, pericardial involvement was transient and no chronic
pericarditis occurred.
Valvular involvement was found in almost 20% of patients
in this study. Valvular disease rate varies widely in literature
(from 1 to 25%) (2, 32). This large difference is probably
related to variable definitions of valvular involvement. In our
study, we considered even slight abnormalities without clinical
consequences as valvular disease. As expected, mitral valve was
affected in the vast majority of cases (32).
The majority of our patients with coronary diameter changes
had good outcome and more than 85% of CAA and dilatations
regressed after the acute phase. This regression rate was higher
than expected, with 50–67% reported in literature (1). This
difference is probably due to an increased recognition of coronary
artery changes, associated with the use of z-scores in spite of
diameters with no correction for BSA. As seen in other studies,
CAA resolution occurredmostly within 2 years after onset of KD.
Absence of IVIG in the acute phase was associated with
less regression rate, which highlight IVIG importance in KD
treatment. Additionally, male gender was associated with greater
z-score on LAD. Thus, close follow-up of male and patients who
did not received IVIG is crucial.
Complications after the acute phase documented in our
patient charts were rare (3.8%) and only 3 patients suffered from
MI during the study. Recurrence of KD was also rare, as seen
in other countries (21). Furthermore, mortality after the acute-
phase of KD was not higher than in the general population,
and the increase in mortality rate among males with cardiac
sequelae reported in a study was not confirmed here (26).
However, it would be useful to continue follow-up of patients
with a history of KD to confirm that their long-term prognosis
remains good. Indeed, at the end of the study period, the oldest
patient was only 36 years of age. It is therefore difficult to define
exactly the cardiovascular prognosis of patients with a history
of KD when they reach middle age. Further trials would be
crucial to determine whether patients with prior KD have higher
cardiovascular risk and could benefit from aggressive prevention
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of known and modifiable risk factor for MI (diabetes mellitus,
hypertension, dyslipidemia, smoking, obesity).
The present study must be viewed in the light of some
limitations. First, it has the limitations of a retrospective
study, with lacking or incomplete information in the patient’s
medical record. Second, the guidelines for KD, and therefore the
management of patients at our Institution, changed throughout
the study period, which makes the follow-up of the patients
included in this article not totally standardized. And as the study
time frame is long, the follow-up of some children is incomplete,
prematurely interrupted due to patients moving or transferred
to adult cardiologist at a different center as the patients grow-
up. Third, there is a bias of selection during the follow-up
at the different times frames, as the follow-up of patients
with transient CAA was shorter than the one with cardiac
sequelae.
Finally, it is a single-center study and extrapolation of our
results needs cautious interpretation. However, as it describes
all patients at a single institution during a long-time frame,
it offers a global picture of KD and its evolution in our
region.
CONCLUSION
In conclusion, this study shows that medium to long-term
prognosis after usual treatment of KD is excellent and the
majority of children do not have any cardiac sequelae or
suffer from complication during the follow-up. Risk factors for
poorer outcome are male gender, atypical age and absence of
IVIG infusion during the acute phase. It is therefore crucial
for physicians to have a high index of suspicion among
children having those characteristics and offer them a strict and
standardized follow-up.
Despite numerous published studies, there remains a lot
unknown about the clinical features and medium to long terms
outcomes in children with KD. Thus, caution is necessary
during follow-up andminimization of known cardiovascular risk
factor is recommended for every patient with a history of KD.
Further prospective multicenter studies are warranted in order
to elucidate all residual interrogations about this disease and to
clarify long-term outcome of KD survivors.
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